Selected article for: "clinical severity and disease duration"
Author: Nicastri, Emanuele; Petrosillo, Nicola; Bartoli, Tommaso Ascoli; Lepore, Luciana; Mondi, Annalisa; Palmieri, Fabrizio; D’Offizi, Gianpiero; Marchioni, Luisa; Murachelli, Silvia; Ippolito, Giuseppe; Antinori, Andrea
Title: National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 clinical management
  • Document date: 2020_3_16
    • ID: 4r0t3q7j_19
    Snippet: A recent study has demonstrated invitro efficacy of chloroquine and remdesivir in inhibiting replication of SARS-COV2. Moreover, emerging reports from China suggests that chloroquine has shown a superiority in reducing both the severity and the duration of clinical disease without significant adverse events in almost one hundred patients. In light of this results, an expert consensus group in China has recommended chloroquine for COVID-19 treatme.....
    Document: A recent study has demonstrated invitro efficacy of chloroquine and remdesivir in inhibiting replication of SARS-COV2. Moreover, emerging reports from China suggests that chloroquine has shown a superiority in reducing both the severity and the duration of clinical disease without significant adverse events in almost one hundred patients. In light of this results, an expert consensus group in China has recommended chloroquine for COVID-19 treatment.

    Search related documents:
    Co phrase search for related documents
    • adverse event and patient adverse event: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adverse event and recent study: 1, 2, 3, 4, 5
    • adverse event and remdesivir chloroquine: 1, 2, 3
    • adverse event and significant patient adverse event: 1
    • adverse event and treatment chloroquine: 1, 2, 3, 4, 5, 6
    • China consensus group and consensus group: 1
    • China consensus group and expert China consensus group: 1
    • clinical disease and consensus group: 1, 2, 3, 4
    • clinical disease and patient adverse event: 1, 2
    • clinical disease and recent study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • clinical disease and remdesivir chloroquine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • clinical disease and result light: 1
    • clinical disease and treatment chloroquine: 1, 2, 3, 4, 5, 6, 7
    • consensus group and expert China consensus group: 1
    • consensus group and recent study: 1
    • consensus group and remdesivir chloroquine: 1
    • patient adverse event and significant patient adverse event: 1
    • patient adverse event and treatment chloroquine: 1
    • recent study and remdesivir chloroquine: 1, 2, 3, 4